UAB expert explains how new FDA-approved drug ushers in a new era of Alzheimer’s treatment

UAB was involved in clinical trials that led to an accelerated approval of the drug lecanemab, commercially known as Leqembi, in January 2023. A UAB Alzheimer’s expert discusses the therapy and what full approval means for the AD field.